Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00147654 · ClinicalTrials.gov registry record · Phase 4

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

A Phase 4 study of Urinary Incontinence, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 4
Development phase
830
Enrollment target
20
Study locations

NCT00147654 is a Phase 4 study of Urinary Incontinence that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 830 participants, above the 245-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (239% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00147654, a Phase 4 study of Urinary Incontinence, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 4
Development phase
830 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).

Conditions Studied

Urinary Incontinence

Interventions

  • DRUG Tolterodine ER 4 mg QD
  • DRUG Tamsulosin 0.4 mg QD

Study Locations (20)

California

  • Pfizer Investigational Site - Anaheim
  • Pfizer Investigational Site - Culver City
  • Pfizer Investigational Site - Fresno
  • Pfizer Investigational Site - La Mesa
  • Pfizer Investigational Site - Long Beach
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Murrieta
  • Pfizer Investigational Site - Poway
  • Pfizer Investigational Site - San Bernardino
  • Pfizer Investigational Site - Santa Monica

Colorado

  • Pfizer Investigational Site - Aurora
  • Pfizer Investigational Site - Boulder
  • Pfizer Investigational Site - Denver

Alabama

  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Homewood

Connecticut

  • Pfizer Investigational Site - New Britain
  • Pfizer Investigational Site - Waterbury

Florida

  • Pfizer Investigational Site - Melbourne
  • Pfizer Investigational Site - Ocala

Arizona

  • Pfizer Investigational Site - Tucson

Trial Details

FieldValue
Enrollment Target 830 participants
Start Date 2004-11
Est. Completion 2006-05
Phase Phase 4

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris

158 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00147654

The ClinicalTrials.gov registry entry for NCT00147654 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 245-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (239% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Tolterodine ER 4 mg QD is the first listed.

NCT00147654 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Alabama.

Frequently Asked Questions

What is clinical trial NCT00147654 about?

NCT00147654 is a clinical study titled "Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction". The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).

What is the current status of trial NCT00147654?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 830 participants. The study started on 2004-11. Estimated completion is 2006-05.

What conditions does trial NCT00147654 study?

This clinical trial studies the following conditions: Urinary Incontinence.

What interventions are being tested in trial NCT00147654?

The interventions under investigation include: Tolterodine ER 4 mg QD (DRUG), Tamsulosin 0.4 mg QD (DRUG).

Who is sponsoring clinical trial NCT00147654?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00147654 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urinary Incontinence

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.